Jefferies Remains Ultra-Bullish on Amarin (AMRN) Ahead of Commercialization Decision

Article Related Press Releases (1) Related Articles (2) Stock Quotes (1) Comments (0)

Jefferies reiterated its Buy rating and $28 price target on Amarin Corporation (NASDAQ: AMRN) following the company's Q3 update.

"We believe the AMRN story near-term remains driven by a key strategic decision on whether to sell company, partner Vascepa, or launch the drug itself," analyst Thomas Wei comments. "We expect this decision to be made in late November. We remain bullish on longt-erm prospects even with self-commercialization and see long-term value in the patent estate with potential stock upside on ANCHOR patent issuances."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $10.26 yesterday, with a 52 week range of $5.99-$15.96.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
• Jefferies Buyers of Jack In The Box (JACK) on Solid Results

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?